bitBiome, Inc. announces that it has resolved the following changes to its Chairman of the Board, CEO and Directors, effective March 26, 2020.
【Purpose of the Change】
Since its inception in November 2018, bitBiome, Inc. has been conducting collaborative research and contract analysis with various institutions through single-cell genome analysis of microorganisms.
With this reorganization, we will strengthen our advantages not only in terms of technology and intellectual property of our original single-cell genome analysis, but also in terms of business, and accelerate the provision of value to society and industry through single-cell genome analysis of microorganisms.
【Details of the Change】
【Biographies of New Appointees】
CEO and chairman of the board Sunao Fujioka
Sunao Fujioka obtained his master’s degree in pharmaceutical sciences at the University of Tokyo. He started his career at McKinsey & Company Japan office, then moved to Janssen Pharmaceuticals, and most recently at MSD, mainly in charge of marketing / business operations.
At MSD, he has led launch of the biomarker / diagnostic field in the oncology business, developed and accelerated novel biomarkers / companion diagnostic adoption in Japan market with relevance to immune-checkpoint inhibitors, such as PD-L1, MSI, etc. He also has marketing experiences in vaccines, gynecologic cancers, breast cancers, and hematology.
He joined bitBiome Inc. in August 2019.
Director, COO Kimihiko Sato
Kimihiko Sato started his career at Mitsui Sumitomo Insurance Company, in the product development department working on actuarial science.
He then worked as a management consultant at Boston Consulting Group for seven years, specific to healthcare industry. Managing a team as a Project Leader, he developed and implemented broad range of strategies such as mid/long-term corporate growth, new product launch, sales, and manufacturing.
He joined bitBiome Inc. in February 2020.